<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Exicure, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      David A. Giljohann
    • FOUNDED
      2009
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Dyadic International, Inc.

    Dyadic International, Inc.

    Dyadic International, Inc. is a global biotechnology company based in Jupiter, Flo...

    Dyadic International, Inc. is a global biotechn...

    Filing Type:    PU
    Provention Bio, Inc.

    Provention Bio, Inc.

    Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...

    Provention Bio, Inc. is a clinical-stage biopha...

    Filing Type:    PU
    Arcturus Therapeutics Holdings Inc.

    Arcturus Therapeutics Holdings Inc.

    Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of...

    Arcturus Therapeutics is developing portfolio o...

    Filing Type:    PU
    Venomyx, Inc

    Venomyx, Inc

    We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...

    We're developing Vipax, the world's first porta...

    Amount Raised:    $290,122.00
    Fundraising Status:    EC
    Filing Type:    CF
    Morphic Holding, Inc.

    Morphic Holding, Inc.

    Morphic Therapeutic is leading the development of a new generation of oral integri...

    Morphic Therapeutic is leading the development ...

    Filing Type:    PU
    Theratechnologies Inc.

    Theratechnologies Inc.

    Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet...

    Theratechnologies (TSX: TH) is a specialty phar...

    Filing Type:    PU
    Genprex, Inc.

    Genprex, Inc.

    Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in ...

    Genprex Inc is a U.S.-based clinical-stage gene...

    Filing Type:    PU
    FibroGen, Inc

    FibroGen, Inc

    FibroGen, Inc. is a leading science-based biopharmaceutical company discovering an...

    FibroGen, Inc. is a leading science-based bioph...

    Filing Type:    PU
    Progenics Pharmaceuticals Inc.

    Progenics Pharmaceuticals Inc.

    Progenics develops innovative medicines and other technologies to target and treat...

    Progenics develops innovative medicines and oth...

    Filing Type:    PU
    Forward Pharma A/S

    Forward Pharma A/S

    Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...

    Forward Pharma A/S is a Danish biopharmaceutica...

    Filing Type:    PU
    Enlivex Therapeutics Ltd.

    Enlivex Therapeutics Ltd.

    Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...

    Enlivex is a clinical stage immunotherapy compa...

    Filing Type:    PU
    Arena Pharmaceuticals, Inc.

    Arena Pharmaceuticals, Inc.

    Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...

    Arena Pharmaceuticals is driven to deliver nove...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.